Mana Rao1, Fernanda P Silveira2. 1. Essen Medical Associates, Bronx, NY, USA. 2. Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, 3601 Fifth Avenue Suite 3A, Pittsburgh, PA, 15213, USA. silveirafd@upmc.edu.
Abstract
PURPOSE OF REVIEW: To review and discuss the epidemiology, risk factors, clinical presentation, diagnosis, and treatment of non-tuberculous mycobacteria (NTM) in thoracic transplantation. RECENT FINDINGS: Non-tuberculous mycobacteria are ubiquitous but are an uncommon cause of disease after solid organ transplantation. The incidence of infection is higher in thoracic transplant recipients than in abdominal transplant recipients, with most cases seen after lung transplantation. It is associated with increased morbidity and, occasionally, mortality. Infection in the pre-transplant setting can occur in lung transplant candidates, often posing a dilemma regarding transplant listing. Disease manifestations are diverse, and pulmonary disease is the most common. Diagnosis requires a high index of suspicion. Treatment requires a multiple-drug combination and is limited by drug-drug interactions and tolerability. Mycobacterium abscessus is a challenge in lung transplant recipients, due to its intrinsic resistance and propensity to relapse even after prolonged therapy. Mycobacterium chimaera is an emerging pathogen associated with contamination of heater-cooler units and is described to cause disease months after cardiothoracic surgery. NTM infections in thoracic organ transplant recipients are uncommon but are associated with substantial morbidity and mortality. Data from larger multicenter studies is needed to better define the epidemiology of NTM in thoracic transplantation, best treatment options, and the management of infected transplant candidates.
PURPOSE OF REVIEW: To review and discuss the epidemiology, risk factors, clinical presentation, diagnosis, and treatment of non-tuberculous mycobacteria (NTM) in thoracic transplantation. RECENT FINDINGS:Non-tuberculous mycobacteria are ubiquitous but are an uncommon cause of disease after solid organ transplantation. The incidence of infection is higher in thoracic transplant recipients than in abdominal transplant recipients, with most cases seen after lung transplantation. It is associated with increased morbidity and, occasionally, mortality. Infection in the pre-transplant setting can occur in lung transplant candidates, often posing a dilemma regarding transplant listing. Disease manifestations are diverse, and pulmonary disease is the most common. Diagnosis requires a high index of suspicion. Treatment requires a multiple-drug combination and is limited by drug-drug interactions and tolerability. Mycobacterium abscessus is a challenge in lung transplant recipients, due to its intrinsic resistance and propensity to relapse even after prolonged therapy. Mycobacterium chimaera is an emerging pathogen associated with contamination of heater-cooler units and is described to cause disease months after cardiothoracic surgery. NTM infections in thoracic organ transplant recipients are uncommon but are associated with substantial morbidity and mortality. Data from larger multicenter studies is needed to better define the epidemiology of NTM in thoracic transplantation, best treatment options, and the management of infected transplant candidates.
Authors: Philipp Kohler; Stefan P Kuster; Guido Bloemberg; Bettina Schulthess; Michelle Frank; Felix C Tanner; Matthias Rössle; Christian Böni; Volkmar Falk; Markus J Wilhelm; Rami Sommerstein; Yvonne Achermann; Jaap Ten Oever; Sylvia B Debast; Maurice J H M Wolfhagen; George J Brandon Bravo Bruinsma; Margreet C Vos; Ad Bogers; Annerose Serr; Friedhelm Beyersdorf; Hugo Sax; Erik C Böttger; Rainer Weber; Jakko van Ingen; Dirk Wagner; Barbara Hasse Journal: Eur Heart J Date: 2015-07-17 Impact factor: 29.983
Authors: S Zaidi; O Elidemir; J S Heinle; E D McKenzie; M G Schecter; S L Kaplan; M K Dishop; D L Kearney; G B Mallory Journal: Transpl Infect Dis Date: 2009-03-09 Impact factor: 2.228